Citadel Advisors’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-42,800
| Closed | -$180K | – | 15799 |
|
|
2023
Q1 | $180K | Buy |
42,800
+10,800
| +34% | +$56.1K | ﹤0.01% | 10364 |
|
|
2022
Q4 | $192K | Buy |
32,000
+18,400
| +135% | +$100K | ﹤0.01% | 10207 |
|
|
2022
Q3 | $79K | Sell |
13,600
-6,800
| -33% | -$42.4K | ﹤0.01% | 11292 |
|
|
2022
Q2 | $122K | Buy |
20,400
+2,700
| +15% | +$13.8K | ﹤0.01% | 11201 |
|
|
2022
Q1 | $83K | Sell |
17,700
-6,600
| -27% | -$19.7K | ﹤0.01% | 12460 |
|
|
2021
Q4 | $60K | Buy |
+24,300
| New | +$59.5K | ﹤0.01% | 13152 |
|
|
2021
Q3 | – | Sell |
-26,400
| Closed | -$66K | – | 15387 |
|
|
2021
Q2 | $66K | Buy |
26,400
+16,300
| +161% | +$39.1K | ﹤0.01% | 13207 |
|
|
2021
Q1 | $29K | Buy |
+10,100
| New | +$33K | ﹤0.01% | 13038 |
|
|
2019
Q2 | – | Sell |
-23,500
| Closed | -$23K | – | 10369 |
|
|
2019
Q1 | $23K | Buy |
+23,500
| New | +$24.7K | ﹤0.01% | 9046 |
|
|
2015
Q4 | – | Sell |
-410
| Closed | -$6K | – | 9775 |
|
|
2015
Q3 | $6K | Sell |
410
-250
| -38% | -$4.32K | ﹤0.01% | 8623 |
|
|
2015
Q2 | $13K | Sell |
660
-2,630
| -80% | -$50.8K | ﹤0.01% | 8343 |
|
|
2015
Q1 | $60K | Buy |
3,290
+210
| +7% | +$4.73K | ﹤0.01% | 7273 |
|
|
2014
Q4 | $73K | Buy |
3,080
+2,590
| +529% | +$59.9K | ﹤0.01% | 6924 |
|
|
2014
Q3 | $12K | Sell |
490
-610
| -55% | -$15.9K | ﹤0.01% | 7720 |
|
|
2014
Q2 | $31K | Sell |
1,100
-1,020
| -48% | -$30.7K | ﹤0.01% | 7071 |
|
|
2014
Q1 | $72K | Sell |
2,120
-430
| -17% | -$14.7K | ﹤0.01% | 6480 |
|
|
2013
Q4 | $49K | Buy |
+2,550
| New | +$46.4K | ﹤0.01% | 6060 |
|
Other funds holding CTIC
Citadel Advisors's CTIC Position: Q2 2023 in Review
Citadel Advisors sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2023, closing a stake of 3,662 shares — an estimated $15.4K sold.
Citadel Advisors first reported a position in CTIC in Q3 2013 and held it in 25 quarters. The position peaked at $4.89M in Q2 2022. 2 funds tracked by Wall St. Rank hold CTIC as of Q2 2023.
- Citadel Advisors reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2023 after selling out during the quarter.
- Citadel Advisors sold 3,662 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2023, an estimated $15.4K.
- Citadel Advisors first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q3 2013 and held it in 25 quarters.
- Citadel Advisors's CTI BioPharma Corp. (DE) Common Stock position peaked at $4.89M in Q2 2022.
- 2 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2023.
Based on Citadel Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.